Experimental squalene adjuvant. I. Preparation and testing of its effectiveness (Q45016408)

8 December 2017

Experimental squalene adjuvant. I. Preparation and testing of its effectiveness (English)

1 reference

8 December 2017

1 reference

Judit Süli

1

1 reference

8 December 2017

Zdenek Benísek

2

1 reference

8 December 2017

Daniel Eliás

3

1 reference

8 December 2017

Stefan Svrcek

4

1 reference

8 December 2017

Anna Ondrejková

5

1 reference

8 December 2017

Róbert Ondrejka

6

1 reference

8 December 2017

Viera Bajová

7

1 reference

8 December 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

8 December 2017

1 reference

8 December 2017

22

1 reference

8 December 2017

25-26

1 reference

8 December 2017

3464-3469

1 reference

The global impact of vaccines containing aluminium adjuvants

8 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.023

Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.023

Recent advances in vaccine adjuvants for systemic and mucosal administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.023

Sulfolipo-cyclodextrin in squalane-in-water as a novel and safe vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.023

Adjuvant effects of sulfolipo-cyclodextrin in a squalane-in-water and water-in-mineral oil emulsions for BHV-1 vaccines in cattle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.023

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.023

Squalene and squalane emulsions as adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.023

Advances in vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.023

An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.023

Postvaccinal sarcomas in the cat: histology and immunohistochemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.023

Vaccine site-associated sarcomas in cats: clinical experience and a laboratory review (1982-1993).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.023

A comparison of commercially available adjuvants for use in research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.023

Syntex adjuvant formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.023

Evaluation of pluronic polyols as carriers for grafting materials: study in rat calvaria defects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.023

Experimental squalene adjuvant. II. Harmlessness and local reactogenity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.02.023

10.1016/J.VACCINE.2004.02.023

7 January 2021

Identifiers

DOI

1 reference

8 December 2017

1 reference